Program Schedule

166
Which One is Best? Antibiotic Choice and Delivery Method in Unique Patients and Settings

Saturday, October 11, 2014: 8:30 AM-10:00 AM
Room: The Pennsylvania Convention Center: Terrace Ballroom-I, II, III, IV
Co-organized with the Society of Infectious Diseases Pharmacists

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe the impact of MIC testing results on optimal drug choice
  • outline novel antimicrobial dosing strategies that may be used in clinical practice
  • identify the clinical scenarios for which combination antimicrobial therapy may be beneficial
  • discuss antimicrobial options and pharmacological strategies for treatment of infections in unique patient populations and/or patient settings

Target Audience: Scientists, Researchers, Pharmacists, Nurses, Microbiologists, Members-in-training, Investigators, Infectious diseases physicians, Infectious diseases pediatricians, Hospital administrators, Health care workers, Fellows, Clinicians, Academicians

Tracks: Pediatric ID, Investigative ID, Global ID, Adult ID

Moderators:  Cesar Arias, MD PhD, University of Texas Medical School At Houston and Sujata Bhavnani, PharmD, Institute for Clinical Pharmacodynamics (ICPD)

Presentations:
9:10 AM
9:30 AM
Combination Therapy
Louis B. Rice, MD

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-14-137-L01-P

Disclosures:

C. Arias, Cubist Pharmaceuticals: Consultant and Speaker's Bureau, Consulting fee and Speaker honorarium
Forest Pharmaceuticals: Speaker's Bureau, Speaker honorarium
Pfizer: Grant Investigator and Speaker's Bureau, Research support and Speaker honorarium
Astra-Zeneca: Speaker's Bureau, Speaker honorarium
Novartis, Inc: Speaker's Bureau, Speaker honorarium
Bayer, Inc: Consultant, Consulting fee

S. Bhavnani, None

T. Lodise, None

B. Tsuji, Cubist: Grant Investigator, Research grant
Forest: Grant Investigator, Research grant
Pfizer: Grant Investigator, Research grant

K. Rodvold, Cubist: Consultant, Scientific Advisor and Speaker's Bureau, Consulting fee and Speaker honorarium

L. B. Rice, Astra-Zeneca: Board Member, Consulting fee
Tetraphase: Consultant, Consulting fee
Trius Pharmaceuticals: Consultant, Consulting fee
T2 Diagnostics: Consultant, Consulting fee

See more of: Interactive Session

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek